Skip to content

Evaluation the effect of one stage full mouth disinfection on serum IL17 and IL23 levels in patients with moderate to severe chronic periodontitis

Evaluation the effect of one stage full mouth disinfection on serum IL17 and IL23 levels in patients with moderate to severe chronic periodontitis

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201103165900N3
Enrollment
33
Registered
2011-04-14
Start date
2010-12-06
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

periodontitis. Chronic periodontitis

Interventions

one-stage full mouth disinfection.
Treatment - Other
one-stage full mouth disinfection

Sponsors

Hamedan dental faculty
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- patients aged 25 to 70 years 2- Having at least 12 teeth (regardless of third molars, teeth with orthodontic appliances, crowns, bridges and implants) 3- Diagnosis of moderate to advanced chronic periodontitis 4- having informed consent. Exclusion criteria: 1- Patients with a contra-indication for surgery or local anesthesia or scaling 2- Systemic disease (eg diabetes mellitus, cancer, AIDS, metabolic bone disease, diseases that delay the healing pockets, previous radiotherapy or immunosuppressive treatment, autoimmune diseases, allergies, infectious diseases, neutropenia, bleeding disorders, Rheumatoid arthritis, bowel disease, lung disease, multiple sclerosis) 3- pregnancy or lactation 4- History of systemic antibiotics use in the past six months 5- History of continuous use of NSAIDS in the past six months 6- scaling and root planning in the past year 7- contagious diseases 8- History of smoking in the past six months

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Serum levels of IL-17. Timepoint: 6 weeks later. Method of measurement: laboratory assessment (IL-17 ELISA kit).

Secondary

MeasureTime frame
Serum IL-23 level. Timepoint: 6 weeks later. Method of measurement: laboratory assessment (IL-23 ELISA kit).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Zarandi

Hamedan dental faculty

zarandi.ali@umsha.ac.ir+98 81 1825 0498

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026